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ABSTRACT  
   
Cancer diseases are among the leading cause of death in the United States.  
Advanced cancer diseases are characterized by genetic defects resulting in 
uncontrollable cell growth. Currently, chemotherapeutics are one of the 
mainstream treatments administered to cancer patients but are less effective if 
administered in the later stages of metastasis, and can result in unwanted side 
effects and broad toxicities. Therefore, current efforts have explored gene therapy 
as an alternative strategy to correct the genetic defects associated with cancer 
diseases, by administering genes which encode for proteins that result in cell 
death. While the use of viral vectors shows high level expression of the delivered 
transgene, the potential for insertion mutagenesis and activation of immune 
responses raise concern in clinical applications. Non-viral vectors, including 
cationic lipids and polymers, have been explored as potentially safer alternatives 
to viral delivery systems. These systems are advantageous for transgene delivery 
due to ease of synthesis, scale up, versatility, and in some cases due to their 
biodegradability and biocompatibility. However, low efficacies for transgene 
expression and high cytotoxicities limit the practical use of these polymers.  
In this work, a small library of twenty-one cationic polymers was 
synthesized following a ring opening polymerization of diglycidyl ethers 
(epoxides) by polyamines. The polymers were screened in parallel and 
transfection efficacies of individual polymers were compared to those of 
polyethylenimine (PEI), a current standard for polymer-mediated transgene 
delivery. Seven lead polymers that demonstrated higher transgene expression 
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efficacies than PEI in pancreatic and prostate cancer cells lines were identified 
from the screening. A second related effort involved the generation of polymer-
antibody conjugates in order to facilitate targeting of delivered plasmid DNA 
selectively to cancer cells. Future work with the novel lead polymers and 
polymer-antibody conjugates developed in this research will involve an 
investigation into the delivery of transgenes encoding for apoptosis-inducing 
proteins both in vitro and in vivo.  
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Chapter 1 
INTRODUCTION 
1.1 Background 
Cancer is one of the leading causes of death in the United States and 
around the world (Yu, Tai, Xue, Lee, & Lee, 2010) among men and women 
younger than 85 years of age (Jemal, 2011). Among the different types of cancer, 
prostate cancer is one of the leading causes of death among men in the United 
States with an estimated mortality rate of 20,093 men in 2007 (Jemal, 2011). In 
addition to prostate cancer, one other form of cancer that has a survival rate of 
less than 5% is pancreatic cancer (Simeone, Cascarelli, & Logsdon, 1997). Even 
with current treatments, the estimated death rates are still projected to increase by 
11% and 6% at the end of 2011 for prostate and pancreatic cancer respectively 
(Siegel, Ward, Brawley, & Jemal, 2011). Due to these alarming statistics, there 
exist a great need for development of new treatments and therapies aimed at 
inducing cancer cell death or suppressing the development of tumors. The use of 
anti cancer agents (chemotherapeutics), given systematically is the currently one 
commonly used method of treatment used in the medical profession (Yu, et al., 
2010). However, these treatments are most effective if a tumor is found in a 
defined localized state in the early stages of metastasis (Merdan, Kopecek, & 
Kissel, 2002). Although chemotherapeutics can be effective to some extent, lack 
of cancer cell specificity leaves a toxic effect not only on cancer cells but also 
healthy cells. This toxicity induces unwanted side effects in patients and requires 
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determination of the correct dosing to achieve a balance between effectiveness 
and toxicity. This presents a great challenge to physicians because patient 
responses to these chemotherapeutic agents vary making under dosing and over 
dosing very problematic (Saha, Vasanthakumar, Bende, & Snehalatha, 2010).  
Cancers diseases have been characterized to result from the presence of 
defective genes that induce uncontrollable cell growth. Recently, alternative 
strategies aimed at correcting these defects have been a highly researched topic. A 
promising method that has been shown to be effective in vitro, involves the use of 
viruses or nanoparticles to deliver either genes (transgene delivery), to correct the 
defective sequences or inhibit their expression, or anti cancer drugs (drug 
delivery). Some advantages to the use of nanoparticles are the ability to control 
the sizes allowing for easier penetration of tumors, and also protecting the genetic 
material from being degraded by DNAses and harmful pH conditions present in 
tumors. This versatility warrants the continued investigation of these systems.  
There have been two modes of transgene delivery that are traditionally 
investigated throughout the literature. One method involves the use of viruses (i.e 
adenoviruses) to deliver genetic materials. Another method is through the use of 
polymeric systems (i.e Polyethylenimine, poly amido-amines, etc). Each of these 
methods offers certain advantages and disadvantages; however, both have 
demonstrated some success for transgene delivery in vitro and in vivo. 
 
 
 3 
1.2 Viral Vectors   
1.2.1 Adenoviral delivery. Use of viruses in gene delivery has been a 
well studied topic throughout the literature. One of the most commonly used 
vehicles is adenoviruses. The use of adenoviruses for delivery of a wide range of 
genes has been shown to be successful in various cancer cells lines both in vitro 
(Kasman, Barua, Lu, Rege, & Voelkel-Johnson, 2009; Park, et al., 2010; Simeone, 
et al., 1997; Varga, et al., 2005) and in vivo (Jounaidi, Chen, Veal, & Waxman, 
2006; Jounaidi & Waxman, 2004). Simeone et al. found a maximum transfection 
of 80 % using an adenovirus with the lacZ adenoviral marker gene (adlacZ) in 
BXPC-3 pancreatic cancer cell line. In addition to the lacZ gene, the 
retinoblastoma gene, which is important in cell cycle regulation, was also 
delivered using the same adenovirus. This resulted in inhibition of cell 
proliferation up to 60 % in BXPC-3, Mia-PaCa-2, and PANC-1 cells (Simeone, et 
al., 1997). Other methods have also been developed using adenoviruses with 
cationic polymers and lipids to induce a synergistic effect that enhanced 
transfection efficacies (Fasbender, et al., 1997; Han, et al., 2010; Kasman, et al., 
2009; MeunierDurmort, Grimal, Sachs, Demeneix, & Forest, 1997), thus 
demonstrating their relevance to cancer therapeutics.  
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1.3 Non-Viral Vectors 
While the use of viral vectors shows high efficiencies and promising 
results, there are some limitations that come with their use. These limitations 
include high immunogenicity triggered by the mammalian immune systems 
leading to elimination of the viral vectors and insertional mutagenesis (Merdan, et 
al., 2002). For these reasons, non-viral vectors have been explored and developed 
as safer alternatives to viral vectors. Most vectors being explored currently are 
polymeric systems which have been shown to be effective. These systems are 
advantageous due to the ease of synthesis, scale up, and versatility (Elsabahy, 
Nazarali, & Foldvari, 2011). These systems can also be designed to be 
biocompatible, biodegradable, and can be functionalized with targeting ligands or 
other enhancers to improve functionality and transfection in cancer cells. 
Throughout the literature, cationic lipids and polymers are a widely investigated 
kind of system. These positively charged molecules possess the ability to bind to 
the negatively charged DNA backbone forming a spherical polymer/DNA 
complex (polyplex), which can interact with the negatively charged cell 
membrane and other surface proteins as illustrated schematically in figure 1. This 
interaction induces uptake of the polyplex into cell via endocytosis resulting in the 
encapsulation of the polyplex in an endosome. According to the proton sponge 
theory (Akinc, Thomas, Klibanov, & Langer, 2005; Berthold, Shiraishi, & 
Nielsen, 2010; Boussif, et al., 1995), due to the acidic nature of the cytoplasm in a 
cancer cell and the high buffering capacity of the polymer, protons are imported 
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into the endosome, resulting in osmotic swelling of the endosomal vesicles. Once 
the osmotic pressure reaches its maximum capacity, endosomal rupture occurs 
releasing the DNA into the cytoplasm where it is speculated to enter the nucleus 
to be processed in a similar manner to the cell’s native DNA.       
 6 
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1.3.1 Polyethylenimine (PEI). PEI is currently the standard for polymer 
mediated transgene delivery and has been studied exhaustively throughout the 
literature. Many have proven continued success with transgene delivery in many 
types of cells using PEI/DNA both in vitro (Boussif, et al., 1995; Cherng, Hung, 
& Kao, 2011; Gabrielson & Pack, 2009; Kang, Kang, & Bae, 2011; M. Lee, 2007; 
Mishra, Kang, & Bae, 2011; Y. H. Wang, et al., 2011) and in vivo (Chumakova, et 
al., 2008; Coll, et al., 1999). This polymer has also been characterized (von Harpe, 
Petersen, Li, & Kissel, 2000) extensively for its intrinsic properties such as 
buffering capacity which is believed to promote endosomal rupturing releasing 
the genetic material into the cytoplasm. This is the defining characteristic that is 
believed to be the contributing factor to the proton sponge effect (Akinc, et al., 
2005; Berthold, et al., 2010; Boussif, et al., 1995; Y. H. Wang, et al., 2011). This 
key feature is also believed to be one of the reasons that PEI has such superior 
transfection efficacies. In addition to the buffering capacity, the size of the 
polyplexes formed using PEI allows for ease of entry into cells by endocytosis. It 
has been proven that the endocytotic range of less than 200 nm is required for 
efficient transgene delivery (Akinc, Lynn, Anderson, & Langer, 2003).  PEI has 
been found to satisfy this requirement forming polyplex sizes that range from 
100-130 nm (Merdan, et al., 2002; Y. H. Wang, et al., 2011). Although this 
polymer seems ideal for use as a non-viral therapeutic agent, there are some 
limitations to its use. One noteable finding throughout the literature is that 
transfection efficiency with PEI is heavily dependent on the molecular weight of 
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the polymer, such that higher molecular weight yields higher transgene expression 
(Godbey, Wu, & Mikos, 1999). However, it has also been determined that 
cytotoxicity increases with increasing molecular weight thus limiting use of this 
polymer beyond these limits (Brunot, et al., 2007). Due to this, many have 
attempted to modify PEI with other moieties such as polyethylene glycol (PEG), 
which was shown to lower cytotoxicity and in some cases enhance gene delivery 
with particles sizes forming within the endocytotic range (Chen, et al., 2011; Peng, 
et al., 2008; Zhang, et al., 2010; Zhuang, et al., 2011). In addition many have used 
PEI to coat the surfaces of adenoviruses to reduce specific interactions, resulting 
in enhanced viral gene delivery (Han, et al., 2010; MeunierDurmort, et al., 1997; 
Varga, et al., 2005). From these examples, it demonstrates that PEI serves as an 
ideal polymer for transgene delivery.  
1.3.2 Addition of targeting ligands for enhanced transgene delivery. It 
is evident that PEI possesses great potential as a non-viral vector for transgene 
delivery. In the previous section, PEI was shown to be used and characterized 
successfully in vitro. One major limitation to its use in vivo is the lack of targeting 
ability towards specific types of cells. In theory, addition of these targeting 
abilities would enhance transgene delivery towards targeted cells by reducing 
non-specific interactions. This would also result in lower cytotoxicity towards non 
targeted cells. Overcoming this problem would make polymeric transgene 
delivery with PEI a more effective treatment in vitro as well as in vivo. It is 
known that many cancers have overexpressed receptors on the cell surfaces that 
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could be used as potential targets for these types of treatments. For example, 
prostate cancer cell overexpress prostate-specific membrane antigen (PSMA) 
(Moffatt, Papasakelariou, Wiehle, & Cristiano, 2006) and breast cancer cells 
overexpress the HER2 antigen (Acharya, Dilnawaz, & Sahoo, 2009; Germershaus, 
Neu, Behe, & Kissel, 2008). Researchers have been able to take advantage of this 
fact by introducing targeting ligands to the polyplexes, such as antibodies that 
have specificity towards these antigens. Many have demonstrated this concept 
successfully by conjugating antibodies to PEI and performed targeted transgene 
delivery to prostate cancer cells (He, et al., 2010; Lu, Jackson, Gleave, & Burt, 
2008; Moffatt & Cristiano, 2006; Moffatt, et al., 2006; Patri, et al., 2004), breast 
cancer cells (Acharya, et al., 2009; Germershaus, et al., 2008), ovarian carcinoma 
cells (Merdan, et al., 2003), and lymphocytes (Buschle, et al., 1995) with positive 
results. With the introduction of the antibodies to the polyplexes, it is expected 
that an increase in the particle size occurs. This was determined not to be true 
with particles that formed within the endocytotic range between 100-230 nm with 
low zeta potentials ranging from ±2 mV - ±6 mV using antibodies and other 
targeting ligands (Germershaus, et al., 2008; Ghiamkazemi, Amanzadeh, 
Dinarvand, Rafiee-Tehrani, & Amini, 2010; Merdan, et al., 2003). Most 
importantly, all groups that have used this concept have all shown higher 
transgene expressions with lower cytotoxicity. With these positive results already 
being shown in vivo (Fujita, et al., 2007), there still exists room for improvement. 
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This could be facilitated with the use of different targeting ligands in combination 
with different polymers. For the time being, this field remains open.  
1.3.3 Poly amido-amines. With toxicity presenting a major limitation to 
the use of untargeted PEI in clinical trials, there exists a need to explore other 
polymers that enhance transfection at higher levels. One other class of polymers 
that has been studied more recently and have shown to be comparable to PEI are 
poly amido-amines. These polymers are synthesized using a Michael type 
addition of various primary or secondary amines to bisacrylamides and have 
shown, in some cases, to have higher transfection efficacies than PEI and form 
polyplexes in the endocytotic range. This class of polymers also has good water 
solubility and biodegradability showing their applicability in transgene and drug 
delivery (Emilitri, Ranucci, & Ferruti, 2005; Guo, et al., 2011) and advantage 
over the non-biodegradable PEI. In addition to these characteristics, it has been 
shown that these polymers have lower cytotoxicity than PEI (R. B. Wang, et al., 
2010), which is attributed to its biodegradability (Ferruti, Marchisio, & Duncan, 
2002). Throughout the literature, modifications have also been performed on these 
polymers such as addition of disulfide linkages to enhance transgene delivery (Lin, 
et al., 2007) and incorporation of hydrophobic moieties (Piest & Engbersen, 2010). 
These modifications have been shown to induce lower surface charge density, 
(Lin & Engbersen, 2008; Lin, et al., 2007; Piest & Engbersen, 2010) while still 
maintaining a buffering capacity higher than PEI (Lin, et al., 2007). Along with 
the biodegradability of the polymer, low surface charge density is another 
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contributing factor to the lower cytotoxicity resulting from less interaction 
between polymer and the negatively charged cellular membrane. Based on these 
results it is encouraging to see that there are potentially other polymers that have 
to ability delivery genes better than PEI with or without modifications.   
1.3.3 Amine-epoxide polymers. Amine-epoxide polymers can serve as 
another potential for transgene delivery as they have been extensively investigated 
and characterized in the literature for their intensive properties and reaction 
kinetics (Ghaemy, Barghamadi, & Behmadi, 2004; Klee, Hagele, & Przybylski, 
2003; Rosu, Mititelu, & Cascaval, 2004; Theis & Ritter, 2010). Synthesis of these 
polymers involves a ring opening polymerization (ROP) of diglycidyl ether 
(epoxide) by polyamines (Guo, et al., 2011; Theis & Ritter, 2010) as shown in 
figure 1.  
 
Figure 2: General scheme for a ring opening polymerization between an amine and epoxide . 
 
For simplicity, figure 2 depicts a linear polymerization although it is possible to 
branching can occur in this type of reaction (Barua, et al., 2009). Although these 
polymers are relatively easy to synthesize, there have been no applications shown 
in the literature. To my knowledge, these polymers have not been thoroughly 
investigated for transgene delivery. Recently, it was found that one amine-epoxide 
polymer, named 1,4 C-1,4 Bis, was shown to have higher transgene expression 
than PEI at certain polymer:DNA weight ratios (Barua & Rege, 2010). These 
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results warranted more investigation into these types of polymers for evaluation 
as potential alternative strategy to viral vectors and forms the basis for 
investigation in this thesis.  
1.4 Conclusion 
Although this is not an exhaustive list of polymers studied, it illustrates the 
potential for their use in transgene delivery. Polymers provide the advantage of 
ease of synthesis, ability to be functionalized, and in some cases are 
biodegradable. In addition, they also possess the ability to carry larger genes than 
viral vectors making them far more practical for gene therapy. Although toxicity 
still remains as one of the limiting factors to the use of polymers, great strides 
have been made to reduce this effect through the incorporation of PEG and other 
functional groups. Even with the advantages to the use of polymers over viral 
vectors outweighing the disadvantages, more research is still needed to exploit the 
full potential of these as gene therapy agents.  
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Chapter 2 
POLYMER SYNTHESIS AND EVALUATION OF TRANSFECTION 
EFFICACY 
2.1 Introduction 
As stated in the previous chapter, polymeric gene delivery systems have 
become a heavily investigated non-viral alternative to viral vectors. Currently, one 
polymer that is commercially available, known as PEI has become the standard 
for polymeric transgene delivery (Merdan, et al., 2002). This is due to the excess 
positive charges on the polymer backbone resulting in effective condensation of 
DNA into nanoparticles allowing for sufficient uptake by cells via endocytosis. 
While this polymer has been shown to be used successfully in vitro, cytotoxicity 
issues arise from its use. More recently, it was discovered that an amine-epoxide 
polymers enhanced transgene delivery at levels higher than PEI at certain 
polymer:DNA weight ratios. It was found that the optimum polymer:DNA ratio 
that gave the highest transgene expression using the polymer name 1,4C-1,4Bis 
was 10:1 (w/w) (Barua & Rege, 2010). Based on this result, it was encouraging to 
see that there is a possibility for polymers synthesized using these types of 
monomers, to produce better transfection efficacies than PEI. This provided the 
motivation behind the work presented in this chapter.        
In this work, synthesis of a library of 26 polymers using the same reaction 
as described in section 1.3.3 occurred. From this library, only 21 polymers were 
successfully synthesized and those polymers were carried forward in transfection 
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studies comparing their respective transfection efficacies to that of PEI at a 
polymer:DNA weight ratio of 10:1. The cell lines used in the experiment were the 
human pancreatic cancer cell line, Mia-PaCa-2 cells and the human prostate 
cancer cell lines, PC-3 cells and PC-3 PSMA cells. From the screening, lead 
polymers were identified as those having greater transfection efficacies than that 
of PEI.  
2.2 Materials and Methods 
2.2.1 Materials. The amines (as shown in figure 3); 2,2 dimethyl-1,3-
propanediamine (1), N-(2-aminoethyl)-1,3-propanediamine (2), 3,3'-Diamino-N-
methyldipropylamine (3), Tris-(2-aminoethyl)amine (4), Diethylenetriamine (5), 
Pentaethylenehexamine (6),  Ethylenediamine (7), Triethylenetetramine (8), 2,2'-
(ethylenedioxy)bis(ethylamine) (9), 1,5-Diamino-2-methylpentane (10), 1,3 
Diaminopropane (11), N,N-Dimethylethylenediamine (12), and 1,3 
Diaminopentane (13) were obtained from Sigma-Aldrich (St. Louis, MO) and 
used as received without any further modification. The ethers (as shown in figure 
4); Neopentyl glycol diglycidyl ether (NPGDE) and 1,4-cyclohexanedimethanol 
diglycidyl ether (1,4C) were also both obtained from Sigma-Aldrich and used as 
received without any further modification. The control polymer, branched 
polyethyleneimine (MW ~ 25,000) was also obtained from Sigma-Aldrich. 
Ninhydrin reagent was purchased from Sigma-Aldrich. Luciferase and BCA 
protein assay kits were purchased from Promega Corporation (Madison, WI) and 
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Thermo Fisher Scientific Inc. (Rockford, IL) respectively. The pGL3 control 
vector was also purchased from Promega Corporation.  
 
NH2H2N
2,2 dimethyl-1,3-propanediamine (1)
H
N NH2
H2N
N-(2-aminoethyl)-1,3-propanediamine (2)
NH2N NH2
3,3'-Diamino-N-methyldipropylamine (3)
N
H2N NH2
NH2
Tris-(2-aminoethyl)amine (4)
H2N
H
N
NH2
Diethylenetriamine (5)
H2N
H
N
N
H
H
N
N
H
NH2
Pentaethylenehexamine (6)
H2N
NH2
Ethylenediamine (7)
H2N
H
N
N
H
NH2
Triethylenetetramine (8)
O
OH2N
NH2
2,2'-(ethylenedioxy)bis(ethylamine) (9)
H2N NH2
1,5-Diamino-2-methylpentane (10)
NH2H2N
1,3 Diaminopropane (11)
N
H2N
N,N-Dimethylethylenediamine (12)
NH2
H2N
1,3 Diaminopentane (13)  
Figure 3: Amine monomers used in the synthesis of the NPGDE and 1,4C libraries. The 
polymers were numbered according to the amines as labeled above. 
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Figure 4: Epoxides monomers used in the synthesis of the NPGDE and 1,4C libraries. The 
libraries were named according to the epoxide used. 
 
2.2.2 Synthesis of the polymers (parallel polymer synthesis). Synthesis 
of the polymers was carried out as a parallel synthesis approach as described 
previously (Barua, et al., 2009). Two libraries of 26 polymers was synthesized 
using the two ethers, 1,4C and NPGDE, and the amines listed above (1-13) in a 
ring opening polymerization (ROP) (Guo, et al., 2011) resulting in 13 polymers 
for each library. Figure 3 shows the structures of all of the amines and figure 4 
shows all of the structures of the epoxides used in the synthesis of these libraries. 
The libraries formed using these monomers will be referred to henceforth as the 
NPGDE library and 1,4C library labeled as such according to the epoxides used to 
form these polymers. Additionally, each polymer was numbered according to the 
numbering system given to the amines in figure 3. The epoxide (1,4C or NPGDE) 
and the amine were mixed in a 1:1 molar ratio in a 4 mL scintillation vial 
(Wheaton) and incubated at room temperature (22°C - 25°C) for 16 hours. After 
16 hours, the resulting polymer was removed from the vial and dissolved in 1X 
PBS (10 mM Na2HPO4, 140 mM NaCl, 27 mM KCl, pH 7.4) to form a polymeric 
solution with a concentration of 10 mg/mL. The pH of the polymer solution was 
adjusted to 7.4 using 6N hydrochloric acid to compensate for the alkalinity of the 
solution (Barua, et al., 2009). The degree of polymerization was determined by 
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quantifying the amine content using the ninhydrin assay (Gabrielson & Pack, 
2009). Briefly, a standard curve was made using glycine with varying amine 
concentrations (0 μM - 250 μM, total volume of 200 μL for each standard). A 1 
mL sample of 5 mg/ml of the resulting polymer was diluted 50X to a total volume 
of 200 μL. 100 μL of ninhydrin reagent was added to each of the standards and 
samples and the absorbance was read using a plate reader (Bio-Tek Synergy 2) at 
a wavelength of 570 nm to quantify the amine concentration of the polymer. Only 
the polymers that were soluble in solution after the 16 hour reaction were carried 
further and used in transfection studies. 
2.2.3 Purification of lead polymers. Purification of the lead polymer 
solutions, as identified from the screening, occurred using a 1000 Da molecular 
weight cutoff (MWCO) membrane. Dialysis occurred in nanopure water for 48 
hours and replacement with fresh water occurred every 12 hours. After 48 hours 
of purification, the polymer solutions were lyophilized, reconstituted in 1X PBS, 
and filtered with a 0.22 μm syringe filter before use in transfection experiments.  
2.2.4 Cells and cell culturing. PC-3 cells (prostate cancer cell line) were 
obtained from the American Type Culture Collection (Manassas, VA), PC-3 
PSMA cells (prostate cancer cell line) were obtained from Dr. Michael Sadelain 
from the Memorial Sloan-Kettering Cancer center (New York, NY), and Mia-
PaCa-2 cells (Pancreatic cancer cell line) were obtained from Dr. Haiyong Han 
from The Translational Genomics Research Institute (Phoenix, AZ). All of these 
cells were cultured in serum containing media (RPMI 1640, 10% FBS, 1% 
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penicillin, 1% streptomycin) and were grown in an incubator under humidified air 
containing 5% CO2 at 37°C.  
2.2.5 DNA purification. DH5α E. Coli cells transformed with the pGL3 
control vector, which encodes for the luciferase protein, under control of the 
SV40 promoter was cultured in 150 mL of terrific broth (MP Biomedicals, Solon, 
OH) containing 100 mg/mL Ampicillin, overnight in an incubator (200 RPM, 
37°C) for 14 hours. The cultures were centrifuged at 6000 RCF at 4°C for 15 
minutes and were purified according to the QIAGEN plasmid purification maxi 
kit protocol (QIAGEN Inc., Valencia, CA). DNA concentration and purity was 
determined by measuring optical density (OD260 and OD280) using the NanoDrop 
spectrophotometer (ND-1000, NanoDrop Technologies). Only DNA within the 
acceptable absorbance range (1.8-2, indicates purity) of the 260 nm: 280 nm ratio 
were used in the transfection experiments. The plasmid was stored at -20 °C until 
use. 
2.2.6 Transfection experiments. Transfection of PC-3, PC-3 PSMA, and 
Mia-PaCa-2 cells using DNA/polymer complexes (polyplexes) consisting of 
pGL3 plasmid DNA and the synthesized polymers was performed. Prior to the 
transfection, cells were seeded at a density of 50,000 cells/well in 500 μl of serum 
containing medium in a 24-well plate and allowed 24 hours for attachement. 
Luciferase plasmid, pGL3, was diluted to a concentration of 50 ng/μL using Tris 
EDTA buffer (Thermo Fisher Scientific, Rockford, IL). Polymer solutions were 
prepared and diluted with 1X PBS to a concentration of 500 ng/μL and filter 
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sterilized by using a 0.22 μm filter. Complexes for transfection were prepared by 
the dropwise addition of 2000 ng (4 μL) of each polymer on top of 200 ng (4 μL) 
of pGL3 plasmid DNA to form a polymer:DNA weight ratio 10:1. Complexes 
were incubated for 20 minutes at room temperature prior to use. Cells were then 
treated with polyplexes in serum free media (RPMI RPMI 1640, 1% penicillin, 
1% streptomycin) for 6 hours in an incubator under humidified air containing 5% 
CO2 at 37°C. Subsequently, the medium was replaced with fresh serum containing 
medium and allowed to incubate for an additional 48 hours. Luciferase protein 
expression, expressed in terms of relative luminescence units or RLU, was 
determined using the luciferase assay kit according to the manufacturer’s protocol 
48 hours after transfection. The luminescence was quantified using the plate 
reader. The protein content in each well was determined using the BCA Protein 
Assay Kit. Transgene expression in all cell lines was calculated and normalized 
with the protein content and expressed as RLU per milligram (mg) protein 
(RLU/mg protein).  
2.2.7 Dose response using the lead polymers. Dose response 
experiments were carried out using the same method as in the previous section. 
From the studies in the previous section, lead polymers were identified as those 
with higher transfection with PEI across all cell lines from each library (NPGDE 
and 1,4C). These leads were purified according to the method in section 2.2.3 and 
were used in subsequent treatments of the cells at different polymer:DNA weight 
ratios. The ratios used in these studies were 1:1, 5:1, 10:1, 20:1, 25:1. and 50:1.    
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2.2.8 Statistical analyses. All experiments were carried out at least in 
triplicate unless mentioned otherwise. The significance between the control and 
each experimental test condition was determined using the two tailed student’s t-
test with p < 0.05 being considered significant. 
2.3 Results and Discussion 
2.3.1 Polymer synthesis. Out of the 26 polymers that were synthesized, 
only 11 of the polymers from the NPGDE library (1-11) and 10 polymers from 
the 1,4C library (1-3, 5-6, and 9-13) were soluble in 1X PBS making a total of 21 
successful polymerizations. The polymers that were insoluble after the 16 hour 
reaction can be explained by the possibility of extensive cross linking. This was 
confirmed physically by the hardness of the resulting polymer that inhibited 
removal from the reaction vial. Ideally, these polymers should be re-synthesized 
with the molar ratios of each monomer adjusted however, with the focus being on 
rapid generation and identification of potential therapeutic polymers, this was not 
employed. All of the successful polymer amine concentrations were quantified 
using the ninhydrin assay (Gabrielson & Pack, 2009). All polymer solutions were 
adjusted to a pH of 7.4 and store in a stock solution at a concentration of 10 
mg/mL. Dilution of the polymer solutions to a concentration of 500 ng/μL was 
performed before use in transfection experiments. 
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2.3.2 Transfection in Mia-PaCa-2, PC-3, and PC-3 PSMA cell lines. 
All three cell lines were transfected with polyplexes consisting of the NPGDE 
library and pGL3 plasmid DNA. Two of the cells lines, Mia-PaCa-2 and PC-3 
cells were transfected using the 1,4C library and pGL3 plasmid DNA. PC-3-
PSMA cells were not used for the evaluation of the 1,4 C library due to 
comtamination issues that surfaced during the screening process. All transfection 
experiments for the purpose of this screening were performed at a 10:1 
polymer:DNA weight ratio as explained previously.  
0
100000
200000
300000
400000
500000
600000
700000
800000
900000
1000000
1 2 3 4 5 6 7 8 9 10 11 PEI
Polymer
Lu
ci
fe
ra
se
 e
xp
re
ss
io
n 
(R
LU
/m
g 
pr
ot
ei
n)
 
Figure 5: Luciferase gene expression (RLU/mg protein) 48 hours after transfection using the 
NPGDE based polymers in Mia-PaCa-2 cells. Only polymers that were soluble in 1X PBS 
after synthesis were used. All Transfections were performed at a polymer:DNA weight ratio 
10:1 (n = 3, * = p < 0.05). P-values were obtained by comparing data from each polymer to 
PEI. All negative luminescence values were not considered significant due to lack of physical 
meaning, and were not included in the calculations. 
 
As shown in figure 5, polymers 3, 4, 5, 6, 8, 10, and 11 from the NPGDE 
library showed higher transfection than PEI with statistical significance (p < 0.05). 
It was calculated that these polymers had between approximately 170 - 700 fold 
* 
* 
* 
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higher luciferase expression in Mia-PaCa-2 pancreatic cancer cells. Through 
visual inspection it was observed that PEI, used at this weight ratio (10:1), 
exhibited high toxicity towards the Mia-PaCa-2 cells, which is presumed to be the 
reason for poor transfection. Polymers 1, 2, 7, and 9 were also screened at this 
condition and showed very poor transfection efficacies. It is worthy to note that 
toxicity was not visually observed with these polymers and thus cannot be the 
explanation for the poor transfection.    
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Figure 6: Luciferase gene expression (RLU/mg protein) 48 hours after transfection using the 
NPGDE based polymers in PC-3 cells. Only polymers that were soluble in 1X PBS after 
synthesis were used. All transfections were performed at a polymer:DNA weight ratio 10:1 
(n = 3, * = p < 0.05). P-values were obtained by comparing data from each polymer to PEI.  
All negative luminescence values were not considered significant due to lack of physical 
meaning, and were not included in the calculations. 
 
A similar trend was observed when using the same NPGDE library with 
PC-3 cells with the exception of polymers 5 and 8, which showed slightly less 
luciferase expression as compared to PEI as shown in figure 6. Polymers 3, 6, and 
11 showed statistically higher transfection efficacy than PEI. These polymers 
* 
* 
* 
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exhibited a 4 - 6 fold higher luciferase expression than PEI. In addition, polymers 
4 and 10 showed a 2 fold higher luciferase expression than PEI. While polymers 4 
and 10 were not statistically significant, the error bars are within reasonable limits 
and thus it is presumed that these results are reliable. Moreover, it was observed 
that PEI was not toxic at this weight ratio in the PC-3 cells, which correlates to 
what was previously shown by others (Barua & Rege, 2010). 
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Figure 7: Luciferase gene expression (RLU/mg protein) 48 hours after transfection using the 
1,4C based polymers in Mia-PaCa-2 cells. Only polymers that were soluble in 1X PBS after 
synthesis were used. Transfections were performed at a polymer:DNA weight ratio 10:1 (n = 
3, * = p < 0.05). P-values were obtained by comparing data from each polymer to PEI.  
 All negative luminescence values were not considered significant due to lack of physical 
meaning, and were not included in the calculations. 
 
Screening of the 1,4 C library in Mia-PaCa-2 cells only showed three 
polymers that had better transfection efficacies than PEI as demonstrated in figure 
7. Polymers 3, 10, and 11 showed statistically higher transfection efficacies of 
about 1700 – 3000 fold over PEI. Interestingly, polymer 6 from this library did 
* 
* 
* 
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not show significant transfection efficacy as was demonstrated with polymer 6 
from NPGDE library even though the amine used to synthesize both was the same. 
Comparing the result for PEI to that shown in figure 5, there exists a correlation 
of toxicity when using PEI to transfect Mia-PaCa-2 cells thus confirming the 
results in both cases are true. This can also accounts for the large fold transfection 
efficacies demonstrated by polymer 3, 10, and 11 from this library.    
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Figure 8: Luciferase gene expression (RLU/mg protein) 48 hours after transfection using the 
1,4C based polymers in PC-3 cells. Only polymers that were soluble in 1X PBS after 
synthesis were used. Transfections were performed at a polymer:DNA weight ratio 10:1 (n = 
3 for all polymers except 3 (n = 2) and 10 (n = 2) , * = p < 0.05). P-values were obtained by 
comparing data from each polymer to PEI. All negative luminescence values were not 
considered significant due to lack of physical meaning, and were not included in the 
calculations. 
 
 
From figure 8, a similar trend was observed in PC-3 cells using the 1,4 C 
library. Polymers 3, 10, and 11 again showed statistically higher transfection 
efficacies than PEI. These polymers showed between 80 - 360 fold higher 
* 
* 
* 
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transfection efficacies than PEI. It was also observed again that polymer 6 did not 
show significant transfection efficacies.  
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Figure 9: Luciferase gene expression (RLU/mg protein) 48 hours after transfection using the 
NPGDE based polymers in PC-3 PSMA cells. Only polymers that were soluble in 1X PBS 
after synthesis were used. Transfections were performed at a polymer:DNA weight ratio 
10:1 (n = 3, * = p < 0.05). P-values were obtained by comparing data from each polymer to 
PEI. All negative luminescence values were not considered significant due to lack of physical 
meaning, and were not included in the calculations. 
 
 
As mentioned previously due to the discovery of contamination with PC-3 
PSMA cells, the 1,4C library was not screened using these cells. Prior to the 
contamination, the NPGDE library was screened and again showed similar trends 
in that the same polymers were able to transfect these cells as was shown in the 
other two cell lines. It was found however, that only polymers 6 and 10 showed 
statistically higher transfection efficacies than PEI showing only between a 2 – 5 
* 
* 
* 
* 
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fold increase. Polymers 3, 4, and 11 showed slightly less transfection efficacy 
than PEI. 
From the results shown in figures 5 – 9, lead candidate polymers can be 
identified as those that consistently showed higher transfection efficacies than PEI 
across multiple cell lines. From the NPGDE library the leads were NPGDE - 3, 
NPGDE - 6, NPGDE - 10, and NPGDE – 11. While NPGDE - 4, NPGDE – 5, and 
NPGDE – 8 showed higher transfection efficacies in some cell lines, they were 
not consistent enough to be considered lead polymers. From the 1,4C library three 
leads were identified and they are 1,4C-3, 1,4C-10, and 1,4C-11. From these 
results it is apparent that the polymers made using amines 3,3'-Diamino-N-
methyldipropylamine (3), 1,5-Diamino-2-methylpentane (10), and 1,3 
Diaminopropane (11) as monomers perform well for transgene delivery. Based on 
the structures of these three amines it is concluded that methylene spacing 
between amine groups plays a crucial role in transfection. It was determined 
previously that DNA binding efficiency is related methylene spacing in that three 
or four methylene spacing in between amine groups showed better DNA binding 
than two methylene spacing (Rege, et al., 2005; van Dam, Korolev, & 
Nordenskiold, 2002). Based on the results obtained from these experiments, this 
result holds true because all three lead amines (3, 10, and 11) have between three 
to five methylene spacing. Additionally, they also showed higher transfection than 
PEI in most cases. This is further confirmed based on the structures of amines 4, 5, 
6, and 8, which all have two methylene spacing, resulting in lower transfection 
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efficacies when compared to the lead amines in most cases. Interestingly, 
Pentaethylenehexamine (6) transfected well when synthesized using NPGDE but 
did not transfect well when synthesized with 1,4C. This may be due to some 
cytotoxicity effects although that was not investigated in these experiments. From 
these results it is valid to conclude that between three and five methylene spacing 
plays a crucial role in transfection. This is explained by increased DNA binding as 
others have shown, which can possibly lead to more effective condensation of the 
DNA allowing easier uptake via endocytosis.   
 
 
 
 
 
 
 
 28 
0
20000
40000
60000
80000
100000
120000
140000
160000
1 to 1 5 to 1 10 to 1 20 to 1 25 to 1 50 to 1
Polymer:DNA weight ratio
Lu
ci
fe
ra
se
 e
xp
re
ss
io
n 
(R
LU
/m
g 
pr
ot
ei
n)
 
Figure 10: Luciferase gene expression (RLU/mg protein) 48 hours after transfection using 
the purified NPGDE based polymer number 3 in Mia-PaCa-2 cells. Transfections were 
performed at various polymer:DNA weight ratios (n = 3) All negative luminescence values 
were not considered significant due to lack of physical meaning, and were not included in the 
calculations. 
 
2.3.3 Dose responses using lead polymers identified from the NPGDE 
library. After completion of the screening, the next logical step is to proceed to 
testing the lead polymers at different polymer:DNA weight ratios which 
henceforth will be referred to as dose responses. This needs to be determined to 
see if these polymers are truly comparable to PEI. Currently, it was discovered in 
the literature that PEI is most effective at a polymer:DNA weight ratio of 1:1 
(Barua & Rege, 2010; Cherng, et al., 2011). Screening of the first lead from the 
NPGDE library (polymer 3) in Mia-PaCa-2 cells showed a typical bell shaped 
curve response (Lin, et al., 2007) with the maximum transfection occurring when 
using polymer:DNA weight ratio of 20:1. It is worthy to note that this polymer 
was purified using the method as described in section 2.2.3 resulting in lower 
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amine content as demonstrated with the ninhydrin assay. This lowering in amine 
content could be a potential explanation for the difference in transfection 
efficacies between the 10:1 from the “unpurified” polymer 3 (ref. figures 5 and 
10) and the purified polymer 3 both of which are from the same library and same 
stock.      
0
50000
100000
150000
200000
250000
300000
1 to 1 5 to 1 10 to 1 20 to 1 25 to 1 50 to 1
Polymer:DNA weight ratio
Lu
ci
fe
ra
se
 e
xp
re
ss
io
n 
(R
LU
/m
g 
pr
ot
ei
n)
 
Figure 11: Luciferase gene expression (RLU/mg protein) 48 hours after transfection using 
the purified NPGDE based polymer number 6 in Mia-PaCa-2 cells. Transfections were 
performed at various polymer:DNA weight ratios (n = 3) All negative luminescence values 
were not considered significant due to lack of physical meaning, and were not included in the 
calculations. 
 
Another lead indentified from the screening of the NPGDE polymers was 
polymer 6. This polymer was carried into the dose response similarly to polymer 
3 from the NPGDE library in Mia-PaCa-2 cells. Results from the dose response of 
the purified NPGDE polymer 6 shows that the optimum ratio occurs at 5:1 (w/w). 
One consistent result that is found from the dose responses from both of these 
polymers is that there exists an optimum ratio at which transfection is the highest. 
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It is also observed that after this optimum ratio, transfection efficacy decreases to 
significantly lower levels. While this was not tested in these experiments, it is 
hypothesized that this may be due to cytotoxic effects. It is known that cationic 
polymers have a tendency to interact with the negatively charged cellular 
membrane thus the possibility of damaging the cells exists (Choksakulnimitr, 
Masuda, Tokuda, Takakura, & Hashida, 1995; Lv, Zhang, Wang, Cui, & Yan, 
2006; Moghimi, et al., 2005). This is primarily due to the excess of positive 
charges on the polyplex surface as demonstrated by zeta potential measurements 
(Kang, et al., 2011; Lin, et al., 2007). While increasing the polymer:DNA ratio 
may result in more effective condensation of the DNA, there also exists issues 
with higher toxicity that has been demonstrated exhaustively with the use of PEI. 
This seems to be the case with the use of these polymers as demonstrated in 
figures 10 and 11. Therefore, it is concluded that there is a need to achieve a 
balance between these two factors in order to have an ideal vector for transgene 
delivery.  
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2.4 Conclusion 
In this chapter, synthesis of a new library of polymers was performed 
using the reaction between an amine and an epoxide in a ring opening 
polymerization (ROP) using the monomers NPGDE and 1,4C with various 
amines. Evaluation of these polymers for transgene expression using the pGL3 
control vector, identified four lead polymers from the NPGDE library and three 
lead polymers from the 1,4 C library that showed up to a 3000 fold higher 
transfection efficacy than PEI at 10:1 polymer to DNA weight ratio. Based on the 
structures of these monomers, it is evident that methylene spacing between 
amines not only play a role in DNA binding (Rege, et al., 2005; van Dam, et al., 
2002) as others have shown but also have a significant effect on transfection 
efficacy. Out of these leads, two were purified and used in dose responsing 
experiments where it was found there exists optimum weight ratios at which 
transfection is the highest. With the data presented here it is concluded that 
polymers synthesized using these monomers hold great potential as gene 
therapeutic agents.  
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Chapter 3 
INTRODUCTION OF AN ANTIBODY AS A TARGETING LIGAND FOR 
IMPROVED TRANSGENE EXPRESSION 
3.1 Introduction 
Conjugation chemistry has been a well explored topic throughout the 
literature. Use of the heterobifunctional linker molecule, N-succinimidyl 3-(2-
pyridyldithio) propionate (SPDP) has been explored greatly in the literature 
(Carlsson, Drevin, & Axen, 1978) mostly due to its diversity and simplicity. 
There are two reactive sites of the SPDP molecule that many researchers take 
advantage of. One end of the molecule contains a highly amine-reactive N-
hydroxysuccinimide (NHS) ester which allows for easy conjugation to amine 
containing molecules such as proteins, antibodies, and polymers similar to PEI. 
The other is a 2-pyridylthio group that is highly reactive with sulfhydryls making 
it easy to bind the linker molecules to each other. This becomes important when 
conjugating antibodies to polymer molecules. This molecule has been used 
extensively in the literature for the conjugation of antibodies to PEI. Performing 
this type of conjugation has been shown to enhance transgene delivery towards 
cancer cells that contain overexpressed antigens on their surfaces (Germershaus, 
Merdan, Bakowsky, Behe, & Kissel, 2006; Germershaus, et al., 2008; Kircheis, et 
al., 1997; J. Lee, et al., 2010; Merdan, et al., 2003; Moffatt, et al., 2006; Slutter, et 
al., 2010).   
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Previously, a library of 80 polymers were synthesized in our lab and 
screened for their respective transgene expressions. One lead candidate, known as 
1,4C-1,4Bis, was identified as having improved transgene expression over PEI at 
certain polymer/DNA weight ratios (Barua, et al., 2009). Since then, this polymer 
has become the golden standard of amine-epoxide polymers. However, it is 
hypothesized that enhanced transgene delivery will result with a targeting ligand 
conjugated to the polymer. The goal of this study was to successfully synthesize 
the polymer-antibody conjugates. Ideally, evaluation would be needed to 
conclude if addition of a targeting ligand to the polyplex would induce an 
improved transgene expression in PC-3 PSMA prostate cancer cells. 
Unfortunately, the evaluation experiments were not able to take place due to 
unforeseen contamination of the PC-3 PSMA cells.  
3.2 Materials and Methods  
3.2.1 Materials. 1,4-cyclohexanedimethanol diglycidyl ether (1,4C) and 
1,4-bis(3-aminopropyl) piperazine (1,4Bis) were both obtained from Sigma 
Aldrich and used as received without any further modification. The monoclonal 
antibody, J591, was obtained from Dr. Neil Bander from Cornell University 
Medical College (New York, NY). The linker molecule, N-succinimidyl 3-(2-
pyridyldithio) propionate (SPDP) and Ellman’s reagent were obtained from 
Thermo Fisher Scientific. Ninhydrin reagent was also obtained from Sigma-
Aldrich. BCA protein assay kit and Dithiothreitol (DTT) were purchased Thermo 
Fisher Scientific Inc. (Rockford, IL). 
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3.2.2 Synthesis of the polymer 1,4C-1,4Bis. Synthesis of this polymer 
was carried out using a synonymous method as described in section 2.2.2 and also 
as described previously (Barua, et al., 2009). 1,4C (269.5 μL) and 1,4Bis (238.2 
μL) were mixed in a 1:1 molar ratio in a 4 mL scintillation vial and incubated at 
room temperature for 16 hours. After 16 hours, the resulting polymer was 
removed from the vial and dissolved in 1X PBS (10 mM Na2HPO4, 140 mM 
NaCl, 27 mM KCl, pH 7.4) to form a polymeric solution with a concentration of 
10 mg/mL. The pH of the polymer solution was adjusted to 7.4 using 6N 
hydrochloric acid to compensate for the alkalinity of the solution (Barua, et al., 
2009). The degree of polymerization was quantified by quantifying the amine 
content using the ninhydrin assay (Gabrielson & Pack, 2009) in the exact manner 
as described in chapter 2. 
3.2.3 Purification of 1,4C-1,4Bis. Purification of the polymer 1,4C-
1,4Bis occurred in the same exact manner as described previously in section 2.2.3. 
1,4C-1,4Bis polymer solution was purified using a 1000 Da molecular weight 
cutoff (MWCO) membrane. Dialysis occurred in nanopure water for 48 hours and 
replacement with fresh water occurred every 12 hours. After 48 hours of 
purification, the polymer solution was lyophilized and reconstituted in 1X PBS.  
3.2.4 Molecular weight determination of the 1,4C-1,4Bis. Gel 
permeation chromatography (GPC) was used to determine the molecular weight 
of the polymer, 1,4C-1,4bis, against Poly (2-vinylpyridine) standards (American 
polymer standards Corporation Mentor, OH). The standard curve was based on 
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five standards (3000, 7000, 12000, 35000, and 70000 Da). This was performed 
using one ultrahydrogel column, (ultrahydrogel 250, Waters Corporation, Milford, 
MA). The mobile phase used was 0.1 M Triflouroacetic acid and 40% 
Acetonitrile at a flow rate of 0.5 mL/min and a column temperature of 35°C. The 
pump used to deliver the polymers to the columns was a waters 1515 isocratic 
HPLC pump and the refractive index was measured with a waters 2414 refractive 
index detector. 
3.2.5 Synthesis of the polymer-antibody conjugates. Synthesis of the 
conjugate was carried out as shown schematically in figure 13. 1,4C-1,4Bis (0.83 
μmol) was dissolved in 1 mL of 1X PBS and reacted with 1.05 μmol (10 mM in 
DMSO) of N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) at room 
temperature for 1 hour under vigorous stirring (Reaction A from figure 7). 
Purification of the product (1,4C-1,4Bis-SPDP) was performed using gel 
chromatography on a PD-10 desalting columns equilibrated with 1 X PBS to 
remove the excess SPDP. Since dilution of the SPDP activated 1,4C-1,4Bis 
occurs, concentration was performed by lyophilization at -48°C and 44 x 10-3 
mbar (Labconco, Kansas city, MO) for 24 hours. Prior to use, the conjugate was 
reconstituted in Nanopure water. Reconstituted SPDP activated 1,4C-1,4Bis was 
reduced for 30 minutes at room temperature using excess dithiothreitol (DTT) to 
produce 1,4C-1,4Bis-SH. The excess DTT was removed using a PD-10 desalting 
column. This sample was again subsequently freeze dried at -48°C and 44 x 10-3 
mbar for 24 hours. Prior to analysis, the 1,4C-1,4Bis-SH  was reconstituted again 
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in Nanopure water. The presence of the –SH group on the polymer was confirmed 
through the use of the Ellman’s reagent according to the manufacturer’s protocol. 
The degree of substitution of SPDP to the polymer was determined using the 
pyridine 2-thione assay according to the manufacturer’s protocol.  
SPDP was conjugated to J591 using a similar method as described above 
(Reaction B from figure 7). J591 (0.013 μmol) in 1 mL of 1X PBS was reacted 
with 0.13 μmol of SPDP (10 mM in DMSO) at room temperature for 1 hour under 
vigorous stirring. Purification of the product was performed using gel filtration on 
a PD-10 desalting columns equilibrated with 1 X PBS to remove the excess SPDP. 
Concentration of the J591 antibody was obtained from the BCA assay according 
to the manufacturer’s protocol. With dilution of the SPDP activated J591 occuring 
from the gel chromatography, concentration was required and performed using 
Slide-A-Lyzer dialysis cassettes (10 MWCO) with the Slide-A-Lyzer 
concentrating solution as described by the manufacturer’s protocol. Concentrated 
SPDP activated J591 was added to the 1,4C-1,4Bis-SH and allowed to react for 
18 hours at 4°C to produce the final antibody-polymer conjugate (Reaction C in 
figure 7). Purification of the conjugate was performed using two different 
methods with an ӒTKA FPLC system equipped with a UV detector (GE 
Healthcare, Piscataway, NJ). First, strong cation exchange chromatography was 
performed with a BioRad Macroprep High S column (40 mm x 5.6 mm, 1 mL). 
Gradient elution was performed using 22-100% buffer A; Buffer A, 3M NaCl and 
20 mM HEPES pH 7.4, Buffer B, 20 mM HEPES pH 7.4. Second, weak cation 
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exchange chromatography was performed with a GE Healthcare Hi Trap CM FF 
column (1.6 cm x 2.5cm, 5 mL). Gradient elution was also performed using 22-
100% buffer A; Buffer A, 3M NaCl and 20 mM HEPES pH 7.4, Buffer B, 20 mM 
HEPES pH 7.4.   
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3.3 Results and Discussion  
 
 
 
 
 
 
 
 
 
 
 
3.3.1 Molecular weight determination. GPC is a very common method 
that is used to characterized polymer molecular weights based on elution times 
(Georgiou, Vamvakaki, Patrickios, Yamasaki, & Phylactou, 2004; Peetz, 
Moustafa, & Kennedy, 2003a, 2003b). Based on the calibration curve obtained 
from the Poly (2-vinylpyridine) standards in figure 13 and the elution time of the 
1,4C-1,4Bis polymer (~16 minutes) as shown in figure 14, it was calculated using 
the machine software that the molecular weight of this polymer, synthesized by 
the method as described in sections 3.2.2. and 3.2.3, is 6000 Da.   
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Figure 13: Calibration curve obtained from the Poly (2-vinylpyridine) standards 
Figure 14: Chromatogram for 1,4C-1,4Bis  
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3.3.2 Conjugation of the antibody (J591) to the polymer (1,4C-1,4Bis). 
Conjugation of J591 to the SPDP molecule (reaction B in figure 12) can be 
verified through the release of the Pyridine-2-Thione group, which has a 
detectable absorbance at 343 nm. The release of this group is induced upon 
addition of excess DTT according to the manufacturer’s protocol and as 
demonstrated in the literature (Germershaus, et al., 2008; Merdan, et al., 2003). 
This same assay can also be used to verify the conjugation of 1,4C-1,4Bis to 
SPDP (reaction A in figure 12).  
Table 1:  
 
Absorbance values confirming linkage of SPDP to J591 
 
A343 prior to addition of DTT (a.u.) A343 after addition of DTT (a.u.) 
0.011 0.128 
       
Based on the absorbance values from table 1 it is shown that there was a definite 
increase in absorbance after mixing the SPDP to J591, showing a difference of 
0.117 absorbance units (a.u) between the readings before and after addition of 
DTT. Using the calculation provided by the manufacturer yields a degree of 
substitution of approximately 2 moles of SPDP per mole of J591.  
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Table 2: 
 
Absorbance values confirming linkage of SPDP to 1,4C-1,4Bis 
 
A343 prior to addition of DTT (a.u.) A343 after addition of DTT (a.u.) 
0.011 0.743 
 
Based on the absorbance values from table 2 it is again observed that an increase 
in absorbance, showing a difference of 0.732 a.u. between the readings before and 
after addition of DTT. The degree of substitution was not able to be conclusively 
determined due to lack of knowledge of the polymer concentration after use of the 
PD-10 desalting column.   
Table 3: 
 
Absorbance values confirming linkage of J591 to 1,4C-1,4Bis 
 
A343 prior to addition of 1,4C-1,4Bis 
(a.u.) 
A343 after addition of 1,4C-1,4Bis  
(a.u.) 
0.011 0.132 
 
Finally upon addition of the –SH functionalized 1,4C-1,4Bis to the J591-SPDP, 
an absorbance change of 0.120 was observed. From this result it can be 
qualitatively concluded that conjugation of the J591 to 1,4C-1,4Bis did occur. 
This is further confirmed by comparing absorbance readings after the addition of 
DTT (A343 after addition of DTT) in both tables 1 and 3. From these absorbance 
values it is clear that the two pyridine-2-thione groups present from the 
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conjugation of J591 to SPDP were released. Without the presence of reducing 
agents, the only logical explanation for is that the 1,4C-1,4Bis-SH successfully 
conjugated to form the final product, J591 conjugated to 1,4C-1,4Bis. 
3.3.3 Purification of the polymer-antibody conjugate. Purification of 
the polymer-antibody conjugate using cation exchange chromatography is a 
necessary step in the synthesis. This ensures the removal of the unconjugated 
antibodies which could potentially interfere with targeted transgene delivery by 
competitive inhibition, in which free antibody could bind to the overexpressed 
antigens instead of the polymer conjugated antibody. This lessens the chance to 
transfect the cells via targeted delivery In order to detect the antibody a UV 
detector set at 280 nm was used. 
 BioradMacroprep high AntibodyJ591:1_UV
   0
 200
 400
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1000
mAU
0.0 1.0 2.0 3.0 4.0 5.0 6.0 min  
Figure 15: Chromatogram of free unconjugated J591 in the BioRad Macroprep high S 
column (Strong cation exchange) 
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The first attempt at purification was done using strong cation exchange 
chromatography. This was performed with BioRad high S column which is the 
column that has been used quite extensively in the literature (Germershaus, et al., 
2006; Germershaus, et al., 2008; Kircheis, et al., 1997). Figure 15 shows the result 
from a control experiment where a 2 milligrams (mg) of the antibody (2 mg/mL, 
1mL) was injected into the system to determine if the antibody exhibits any 
binding to the column using a gradient elution of 22% - 100% buffer A; Buffer A, 
3M NaCl and 20 mM HEPES pH 7.4, Buffer B, 20 mM HEPES pH 7.4. This was 
a necessary experiment because in theory, the polymer antibody conjugate should 
elute at a different retention time (RT) than the antibody due to the interaction of 
the polymer (1,4C-1,4Bis) with the column. It was confirmed that the antibody 
did not bind to the column as is evident by single large peak that appears at a RT 
of about two minutes, corresponding to a 0% buffer A. This result was found to 
be consistent with the literature results (Germershaus, et al., 2006; Merdan, et al., 
2003). This was further confirmed by the BCA assay which verified that mass 
was conserved (~2 mg elution from the column).    
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Figure 16: Chromatogram of the polymer-antibody conjugate in the BioRad Macroprep 
high S column (Strong cation exchange) 
 
With the result from the control experiment confirmed, the polymer - 
antibody conjugate was subsequently injected into the system. Consistent with the 
previous result, the free antibody eluted from the column at a RT of ~ two 
minutes which corresponds to 0 % buffer A. Performing BCA assay on this 
fraction confirms negligible amounts of antibody are present indicating that most 
of the antibody has been conjugated to the antibody. Interestingly, there was not 
second peak that is representative of the polymer-antibody conjugate. It has been 
shown in the literature that the polymer- antibody conjugate should elute towards 
the end of the gradient where a high concentration of buffer A is applied to the 
column (Germershaus, et al., 2006; Merdan, et al., 2003). This was not the case 
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with this polymer-antibody conjugate as shown in figure 16 due to the lack of a 
second peak. This is a strong indication of an unknown interaction between the 
polymer-antibody conjugate and the column functional ligand  
(SO3 2-), possibly hydrogen bonding, that is not allowing elution of the polymer – 
antibody conjugate from the column.   
 
 GE column weak cation exchange antibody alone 6202011:1_UV
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Figure 17: Chromatogram of free unconjugated J591 in the GE Healthcare Hi Trap CM FF 
column (weak cation exchange column) 
 
Due to the previous result, it hypothesized that using a weaker binding 
column (GE Healthcare Hi Trap CM FF column) with a different functional 
ligand (-COOH) would allow for elution of the polymer-antibody conjugate. 
Before this could be performed the same control experiment was performed and 
the results are presented in figure 17. There exist two separate and distinct 
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antibody peaks present, indicating that the antibody binds to the column. The first 
peak, corresponding to 0% buffer A, shows the antibody elutes at a RT of five 
mintues. The second peak, also representative of an antibody, corresponds to 
~11% - 13% buffer A with an RT of approximately twenty minutes. BCA assay 
confirms that the sum of both fractions yields approximately 2 mg, thus mass is 
conserved. 
 
 GE column weak cation exchange conjugate final 62011:1_UV
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Figure 18: Chromatogram of the polymer-antibody conjugate in the GE Healthcare Hi Trap 
CM FF column (weak cation exchange column) 
 
Finally, the polymer - antibody conjugate was injected into the system and 
the same gradient elution protocol was used. The results in figure 18 show 
consistency with the control experiment in that there is a small peak present at a 
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RT of five minutes. There is a second peak that exists at a RT of approximately 
twenty five minutes corresponding to 42% buffer A. This is not indicative of free 
antibody as demonstrated in figure 15 (RT = 20 mintues) but could possibly be 
the polymer - antibody conjugate. Further characterizations are needed in order to 
prove that this is true.   
3.4 Conclusion  
In this chapter, synthesis of the polymer-antibody conjugate using the 
polymer 1,4C-1,4Bis and the PSMA antibody J591, was performed using the 
heterobifunctional linker molecule, SPDP. The results show a strong indication 
that the polymer-antibody conjugate did form however, further characterizations 
are needed to determine the polymer:antibody ratio of the conjugate. In addition 
to the synthesis, purification of the polymer-antibody conjugate was attempted 
using both a strong cation exchange column (BioRad High S) and a weak cation 
exchange column (GE Healthcare CM FF) in order to separate the excess 
antibody. It was determined that there exists strong interactions between the 
polymer and the functional ligands thus inhibiting elution of the polymer-antibody 
conjugate from the BioRad high S column. Performing the separation using the 
GE Healthcare CM FF column yielded a second peak with a different elution time 
than was shown in the control experiment, indicating the possibility of the elution 
of the conjugate. With the data presented in this chapter, it is concluded that 
polymer-antibody conjugate was successfully synthesized with purifications still 
needed.  
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Chapter 4 
FUTURE WORK 
4.1 Chapter 2 Future Work  
4.1.1 Purification of the polymer solutions. While this process has 
already begun, the rest of the lead polymers, as identified in chapter 2, need to be 
purified via dialysis using a 1000 Da MWCO membrane against water. This will 
ensure that all excess amines, which are soluble in water, are removed from the 
solution. The excess amines present a potential problem in that they can also bind 
to the DNA and occupy binding sites where the polymer usually binds. This could 
result in less condensation of the DNA which could inhibit endocytotic uptake 
and in addition also contribute to higher cytotoxicity. With all of the excess 
monomer removed from the polymer solution, it is speculated that only the 
polymer will bind to the DNA. This could lead to more efficient condensation of 
the DNA and allow higher transfection efficacy due to smaller particle sizes. 
Currently, PEI/DNA forms spherical particles with sizes that range from ~100 nm 
-150 nm (Merdan, et al., 2002; Y. H. Wang, et al., 2011). It is hypothesized that 
with the removal of the monomer, sizes to similar to that of PEI can be formed 
thus yielding more efficient DNA delivery.  
4.1.2 Molecular weight determination. Molecular weight of the purified 
lead polymers should be measured using the same methods as described in section 
3.2.4. Molecular weight determination is important because it has been shown that 
lower molecular weight polymers exhibit lower toxicity (Merdan, et al., 2002). 
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Unfortunately, low molecular weight polymers also have a lower transfection 
efficacy. Although this does not seem to be the ideal case, it is possible to 
functionalize the polymers with side groups that lower toxicity while enhancing 
transfection. It is encouraging that the molecular weight of 1,4C-1,4Bis which 
was synthesized using the same method as NPGDE and the 1,4C libraries, had a 
low molecular weight (6000 Da) after purification. This demonstrates the 
possibility that the polymers in the NPGDE and 1,4C libraries will have similar 
molecular weights.  
4.1.3 Structural studies. Structural determination of the polymers is a 
necessary characterization. This allows for more valid conclusions on polymeric 
properties that enhance transgene delivery. Structural studies should be performed 
using 1H NMR and FT-IR. Both of these techniques will allow for sufficient 
characterization of the polymers and will allow a valid conclusion on the 
structures of all of the polymers.  
4.1.4 Particle size and surface charge determination. Particle size and 
zeta (ζ)-potential of the polyplexes should be determined by dynamic light 
scattering (DLS). This should be performed with the purified polymers to 
determine if they are comparable to PEI. 
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4.1.5 Dose response with lead polymers. While the results shown in 
chapter 2 seem to be very promising use of a polymer to condense DNA at a 10:1 
polymer:DNA weight ratio is not ideal. It has been shown that use of PEI at a 1:1 
polymer:DNA weight ratio has the highest transfection efficacy (Barua & Rege, 
2010; Cherng, et al., 2011) proving yet again why this polymer is the standard for 
polymeric transgene delivery. In order to determine whether the lead polymers 
found in this study are truly more efficient than PEI, transfection studies will need 
to be performed at varying polymer:DNA weight ratios, which is work that is 
currently being performed. The weight ratios that are planned to be tested are 1:1, 
5:1, 10:1, 20:1, 25:1, and 50:1. Only after these experiments are carried out can a 
valid conclusion be made as to whether these polymers are more efficient at 
delivering DNA to the three cell lines mentioned above. Currently, the optimum 
polymer:DNA ratio that has been shown to be the most effective when using PEI 
to condense reporter genes such as pGL3 and E-GFP is a 1:1 (w/w) (Barua & 
Rege, 2010; Cherng, et al., 2011), which has also been confirmed in our lab to be 
true 
4.1.6 Cytotoxicity studies. In addition to evaluating the transgene 
delivery of the polyplexes, toxicity studies also need to be performed. 
Cytotoxicity of the polyplexes should be evaluated using the methyl thiazolyl 
tetrazolium (MTT) assay to validate the claims made in chapter 2.  
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4.2 Chapter 3 Future Work 
4.2.1 Purification of the polymer-antibody conjugates. As shown 
previously in chapter 3, purification of the polymer-antibody conjugates has been 
a great challenge. This step of the process is necessary because there exists the 
possibility that unconjugated antibody is present in the solution along with the 
polymer-antibody conjugate. This presents a problem in that these free antibodies 
can occupy the PSMA binding sites over-expressed on the surface of PC-3 PSMA 
cells, thus lowering the potential of gene delivery using the antibody-polymer 
conjugate. Throughout the literature, it has been found that separation of the 
unconjugated antibody from the polymer-antibody conjugate has been fairly 
simple (Ref. Figures 15 and 17). However, due to some unknown interactions the 
polymer-antibody conjugate has not been shown to elute from the columns in this 
case. This is proven by the one peak that is present on all of the chromatograms 
using the strong cation exchange column, without the presence of the second peak 
that is representative of the antibody-polymer conjugate as demonstrated by 
others (Germershaus, et al., 2006; Germershaus, et al., 2008; Kircheis, et al., 
1997). One hypothesis for these unknown interactions is the possibility of 
hydrogen bonding between the functional ligand of the columns and the polymers. 
In addition separation using the weak cation exchange column has not shown to 
be greatly successful as well possibly for the same reasons. Changing of pH of the 
elution buffers may alleviate some of these binding effects and allow for easier 
elution of the polymers. Changing of the composition of the buffers may also aid 
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in elution. For example, using CaCl2 instead of NaCl could help better displace 
the polymer. However, use of CaCl2 should be monitored very carefully due to the 
possibility of precipitation onto the column which could result in loss of the 
polymer-antibody conjugates and loss of column functionality.  
4.2.2 Cell transfection studies with PC-3 PSMA cells. Following 
completion of the polymer-antibody conjugates synthesis and purification, 
transfection studies are needed to if enhanced transgene delivery occurs in PC-3 
PSMA cells. In theory, transgene delivery should be enhanced, to some extent, 
due to addition of the targeting ligand as previously shown in the literature 
(Buschle, et al., 1995; Germershaus, et al., 2006; Germershaus, et al., 2008; 
Kircheis, et al., 1997; J. Lee, et al., 2010; Merdan, et al., 2003; Moffatt, et al., 
2006). These results are encouraging and should be confirmed using the conjugate 
formed using 1,4C-1,4Bis and compared against the conjugate formed using PEI. 
The experiment should be performed using the same polymer:DNA weight ratios 
as previously described in section 4.1.5 and in addition should be compared 
against the untargeted polyplexes. 
4.2.3 Cytotoxicity studies. Using the same methods as described in 
section 4.1.6, the cytotoxicity of the complexes formed from the polymer - 
antibody conjugates and DNA will be evaluated. These studies are important to 
determine what ratios are toxic to cells and to see whether these results correlate 
with published literature values.   
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4.2.4 Structural studies. Structural determination of the complexes 
formed from the antibody-polymer/DNA is a necessary characterization. This will 
ensure that the conjugation of the antibody to the polymer was successful and will 
give insight as to where binding of the SPDP linker molecule binds on the 
antibody. This becomes an important factor because if the SPDP molecule 
interferes with the antigen binding sites, lower transfections could potentially 
result due to inefficient binding of the antibody. Structural studies will be 
performed using 1H NMR and FT-IR. Both of these techniques will allow for 
sufficient characterization and will allow a valid conclusion on the structures of 
all of the complexes.         
4.2.5 Particle size determination. Determination of the size and zeta 
potential will need to be evaluated on the antibody-polymer/DNA complex using 
the same methods as described in section 4.1.4.  
4.2.6 Click chemistry. Although conjugation using the linker molecule 
SPDP was shown to be effective, the efficiency of the reaction remains in 
question. Other alternative conjugation methods exist that claim to be better than 
heterobifunctional linkers. One method that has been used in the literature is 
commonly known as click chemistry. Antibodies are typically conjugated to 
nanoparticles through a copper-catalyzed terminal alkyne-azide cycloaddition 
(CuAAC) (Elias, Cheng, & Tsourkas, 2010; Thorek, Elias, & Tsourkas, 2009). 
This same concept could be employed with the polymers synthesized in this thesis 
and efficiencies between the use of SPDP and CuAAC should be compared. 
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